Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14272795 | 0.91 | CD44 (0.65) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL1770635 | 0.83 | CD44 (0.54) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL9634914 | 0.82 | CD44 (0.75) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL29739478 | 0.82 | CD44 (0.75) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL4508097 | 0.79 | TSHR (0.63) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL30888659 | 0.79 | CD44 (0.48) | CD44GAACYP3A4TSHRALDH1A1 | |
| SCHEMBL404439 | 0.79 | CD44 (1.00) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL8121628 | 0.79 | CYP3A4 (0.55) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL3342238 | 0.79 | GAA (0.53) | CD44GAACYP3A4TSHRMAPK1 | |
| SCHEMBL203360 | 0.77 | CD44 (0.75) | CD44GAACYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017101890-A1 | SPIROKETAL DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION | 上海艾力斯医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-101238131-A | Bridged piperazine and piperidine derivatives as CCR1 antagonists | NOVARTIS AG (CH) | 2008-08-06 | — | — | CN | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| EP-1155012-B1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6699861-B1 | ANTI-CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | FABP1, FABP5, FABP2 | CD44 4254/4885GAA 3457/4885CYP3A4 1971/4885 |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | CD44 4750/4885GAA 82/4885CYP3A4 59/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | CD44 896/4885GAA 2746/4885CYP3A4 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.